GlassScriptPhysician profile
Wade Vincent Harvey
NPI 1457565558
$3,933.78
in general payments reported to CMS, 2019-2025
34 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $313 · 2021: $699 · 2022: $897 · 2023: $866 · 2024: $474 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $524.92 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $509.62 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $479.95 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $328.18 | 2019-2024 | Verquvo, Vaxneuvance, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.34 | 2019-2024 | Synjardy, Tradjenta, Jardiance |
| Abbott Laboratories | $246.86 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $177.46 | 2022-2025 | Brilinta, Airsupra |
| Pfizer INC. | $163.98 | 2019-2025 | |
| Amgen INC. | $124.46 | 2021-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $106.02 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $95.91 | 2019-2023 | |
| Amarin Pharma, INC. | $89.98 | 2020-2021 | |
| Glaxosmithkline, LLC. | $87.60 | 2020-2023 | Shingrix, Bexsero, Pediarix |
| Esperion Therapeutics, INC. | $86.07 | 2021-2025 | Nexletol |
| Mylan Specialty L.P. | $74.53 | 2021-2023 | Yupelri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $72.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.95 | 2020-2024 | Xifaxan |
| Avanir Pharmaceuticals, INC. | $52.45 | 2021-2022 | |
| Edwards Lifesciences Corporation | $52.14 | 2021 | |
| Currax Pharmaceuticals LLC | $42.53 | 2021-2024 | Onzetra Xsail, Contrave |
| Philips North America LLC | $39.07 | 2021-2022 | |
| Organon LLC | $36.44 | 2022-2023 | Nexplanon |
| Verona Pharma, INC. | $28.29 | 2025 | Ohtuvayre |
| Stryker Corporation | $27.64 | 2025 | Flowtriever |
| Phathom Pharmaceuticals, INC. | $20.79 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $20.56 | 2021 | |
| Scynexis, INC. | $18.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.06 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2024 | Eliquis |
| Alkermes, INC. | $16.15 | 2023 | Aristada, Lybalvi |
| Sanofi Pasteur INC. | $15.80 | 2023 | |
| Therapeuticsmd, INC. | $14.62 | 2021 | |
| Boston Scientific Corporation | $14.38 | 2021 | |
| Dexcom, INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.